MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer

Beatriz Germán(Henry M. Jackson Foundation), Leigh Ellis(Prostate Cancer Research)

bioRxiv (Cold Spring Harbor Laboratory)

February 2, 2024

10.1101/2024.01.31.578216

Cited by 2

Related Papers

Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma

|Nature Communications|2021|167

The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy

|Blood|2009|112

Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models

|Cancer Immunology Research|2014|90

Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation

|Cancer Cell|2025|20

Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies

|Cell Death and Disease|2015|18